Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|APTO-253||APTO-253 is a small molecule that induces expression of KLF4 and CDKN1A, resulting in decreased tumor cell proliferation, cell-cycle arrest, and apoptosis, and has been shown to induce DNA damage (PMID: 26268924, PMID: 29626127, PMID: 29626126).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lymphoma||not applicable||APTO-253||Preclinical - Cell culture||Actionable||In a preclinical study, APTO-253 treatment in acute myeloid leukemia cell lines resulted in decreased proliferation in culture (PMID: 29626127).||29626127|
|Unknown unknown||Advanced Solid Tumor||not applicable||APTO-253||Phase I||Actionable||In a Phase I clinical trial, APTO-253 demonstrated safety and resulted in stable disease in 24% (5/32) of evaluable solid tumor patients (PMID: 26268924).||26268924|
|Unknown unknown||acute myeloid leukemia||not applicable||APTO-253||Preclinical - Cell culture||Actionable||In a preclinical study, APTO-253 treatment in acute myeloid leukemia cell lines resulted in decreased proliferation, cell-cycle arrest, and induced apoptosis in culture (PMID: 29626127).||29626127|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02267863||Phase I||APTO-253||A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS||Recruiting|